# EDGAR Filing Document

**Accession Number:** 0001140859
**File Stem:** 0001104659-23-005999
**Filing Date:** 2023-1
**Character Count:** 9985
**Document Hash:** 9d36296125a11fd46d9e15dd7521f75a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-005999.hdr.sgml**: 20230124

**ACCESSION NUMBER**: 0001104659-23-005999

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230124

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230124

**DATE AS OF CHANGE**: 20230124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMERISOURCEBERGEN CORP
- **CENTRAL INDEX KEY:** 0001140859
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **IRS NUMBER:** 233079390
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-16671
- **FILM NUMBER:** 23545866

**BUSINESS ADDRESS:**
- **STREET 1:** 1 WEST FIRST AVENUE
- **CITY:** CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428
- **BUSINESS PHONE:** 6107277000

**MAIL ADDRESS:**
- **STREET 1:** 1 WEST FIRST AVENUE
- **CITY:** CONSHOHOCKEN
- **STATE:** PA
- **ZIP:** 19428

?xml version="1.0" encoding="utf-8"?

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 24, 2023

**AmerisourceBergen Corporation**

**__________________________________________**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| Delaware | 1-16671 | 23-3079390 |
| (State or other jurisdiction  | <br> (Commission  | <br> (I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| 1 West First Avenue<br> Conshohocken, PA |  | <br> 19428-1800 |
| (Address of principal executive offices)  |  | (Zip Code)  |

---

Registrant's telephone number, including area code: (610) 727-7000

Not Applicable

____________________________________________

Former name or former address, if changed since last report

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**<u>Title of each class</u>** | &nbsp;&nbsp;**<u>Name of exchange on which<br> registered</u>** |
| &nbsp;&nbsp;Common stock &nbsp;&nbsp;ABC | &nbsp;&nbsp;New York Stock Exchange (NYSE) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp; ◻

**Item 7.01. Regulation FD Disclosure.**

On January 24, 2023, AmerisourceBergen Corporation (the "Company") issued a news release announcing its intent to change its name to Cencora in the second half of calendar year 2023. The news release is being furnished with this Current Report as Exhibit 99.1 and is incorporated herein by reference.

When the Company begins operating as Cencora, it also intends for its Common Stock to cease trading under the ticker symbol "ABC" and to begin trading on the New York Stock Exchange under the ticker symbol "COR".

The information in this item, including Exhibit 99.1, is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. This information shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| [99.1](tm234123d1_ex99-1.htm) | [News release of AmerisourceBergen Corporation, dated January 24, 2023.](tm234123d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | AMERISOURCEBERGEN CORPORATION | AMERISOURCEBERGEN CORPORATION |
| January 24, 2023 | By: | /s/ Elizabeth S. Campbell |
|  | Name: | Elizabeth S. Campbell |
|  | Title: | Executive Vice President & Chief Legal Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**AmerisourceBergen Announces Intent to Change Name to Cencora**

*Unified corporate identity reflects the organization's global reach, impact, and purpose*

**CONSHOHOCKEN, Pa. (January 24, 2023)** – AmerisourceBergen (NYSE: ABC) today announced its intent to change its name to better reflect its bold vision and purpose-driven approach to creating healthier futures. AmerisourceBergen intends to become Cencora. The new name represents a unified presence that will continue to fuel the company's ongoing growth strategy and advance its impact across healthcare.

"Over time, we have established ourselves as a trusted industry partner that prioritizes innovation, advocates for patient access, and advances strategic partnerships across the global pharmaceutical supply chain. To further bolster our position, we must continue to adapt and evolve within our dynamic industry as we pursue the goal of enhancing health outcomes. Building a unified brand is fundamental to our identity as a global healthcare company. We believe our new name better reflects who we are today and our impact across pharmaceutical care," said Steven H. Collis, Chairman, President & Chief Executive Officer of AmerisourceBergen.

The name Cencora is inspired by customers and team members around the world. In addition, a shared identity will create a more inclusive experience for employees as well as a stronger employer brand to attract talent and increase employee loyalty, retention, and performance. The name tells a compelling story, boldly differentiates the company, and was created with a future-oriented mindset. AmerisourceBergen intends to begin operating as Cencora in the second half of calendar year 2023.

The change to Cencora is aligned with the organization's growth strategy and continued emphasis on innovation. AmerisourceBergen has focused on supporting pharmaceutical advancement and access for patients, manufacturers, and providers across the global healthcare supply chain.

Operating as Cencora, a unified and internationally inclusive name and brand, the company will continue to invest in and focus on its core pharmaceutical distribution business, while also growing its platform of pharma and biopharma services to support pharmaceutical innovation and access.

For more information, visit: <u>www.cencora.com</u>

**About AmerisourceBergen**

AmerisourceBergen is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 44,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #10 on the Fortune 500 and #21 on the Global Fortune 500 with more than $200 billion in annual revenue. Learn more at www.amerisourcebergen.com.

*Cautionary Note Regarding Forward-Looking Statements*

Any statements included in this current report which pertain to future financial and business matters are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management's current expectations and are subject to numerous risks, uncertainties and other unpredictable or uncontrollable factors which could cause future results to differ materially from those expressed in the forward-looking statements. The forward-looking statements speak only as of the date of this report and the Company undertakes no obligation, and does not intend, to update these forward-looking statements to reflect events or circumstances occurring after the date of this report. Additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) in Item 1A (Risk Factors), in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2022 and elsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act, which are available at investor.amerisourcebergen.com.

**Contacts:**

**Media:**<br> Lauren Esposito<br> 215-460-6981<br> <u>lesposito@amerisourcebergen.com</u>

**Investors:**<br> Bennett S. Murphy<br> 610-727-3693<br> <u>bmurphy@amerisourcebergen.com</u>